LXG6403 NEW

We’re proud to offer LXG6403, a highly potent and irreversible lysyl oxidase (LOX) inhibitor, now available from Zibo Hangyu Biotechnology Development Co., Ltd. This compound shows great promise in triple-negative breast cancer (TNBC) research, especially in enhancing chemotherapy effectiveness.

 Key Highlights:

✔️ IC₅₀ = 1.3 μM in MDA-MB-231 cells

✔️ >3x selectivity for LOXL2; no activity against LOXL1

✔️ Enhances chemotherapy response in TNBC cell lines and patient-derived organoids

✔️ Reverses doxorubicin resistance in vivo

✔️ Inhibits FAK signaling and boosts ROS/DNA damage response

✔️ Reduces collagen cross-linking, improving drug delivery in 3D cultures

Flexible Supply Options:

Available in milligram, gram, and kilogram quantities—ideal for both early research and scale-up projects.